Revolution names new CMO
This article was originally published in Scrip
Revolution Medicines, a company focused on the development of drugs derived from natural compounds, has named Dr Carole A Sable chief medical officer. Dr Sable will lead the company's clinical development strategy and execution, with an initial focus on its antifungal program. She joins Revolution from Scynexis, a company that develops new anti-infective drugs, where she was also chief medical officer.